Over the past decade, Alta Partners has built a strong and diversified portfolio. Alta has invested in over 150 companies, including some of the leaders in the biopharmaceuticals, medical technology, and information technology sectors.
Recent Additions
 |
ATS Medical, Inc. Minneapolis, Minnesota ATS Medical, Inc. is a leading developer, manufacturer and marketer of products and services focused on cardiac surgery. Nasdaq: ATSI Contact: Guy P. Nohra |
 |
Esperion Therapeutics (spin-out) Ann Arbor, MI Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function Contact: Alison de Bord |
 |
Excaliard Pharmaceuticals Encinitas, California Excaliard is a private biotechnology company focused on the development and commercialization of antisense drugs for the local treatment of scarring and other fibrotic diseases. Contact: Farah Champsi |
 |
Immune Design Co. Seattle, Washington Immune Design Corp. is a Seattle-based biotechnology company focused on developing a broad platform of novel vaccines (both therapeutic and prophylactic) for the treatment of infectious disease. The Company's technologies regulate immunity by targeting dendritic cell responses with combinations of proprietary viral vectors, TLR agonists, and adjuvants. Contact: Ed Penhoet, Ph.D. |
 |
Kiadis Pharma Groningen, The Netherlands Kiadis is a private transatlantic company headquartered in Amsterdam with sites in Groningen (the Netherlands) and Montreal (Canada). Its product pipeline is focused on novel treatments for significant unmet medical needs in the field of bone marrow transplants. The lead products are currently in clinical trials, ranging from Phase I/II to entering Phase III. Contact: Katya Smirnyagina, Ph.D. |
 |
Sierra Surgical Technologies Palo Alto, CA Sierra Surgical Technologies is a developer of minimally invasive surgical systems. Contact: Alison de Bord |
 |
Sonexa Therapeutics, Inc. San Diego, California Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. Contact: Robert Alexander, Ph.D. |
 |
Sutro Biopharma Menlo Park, California Sutro Biopharma is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics. Contact: David Mack, Ph.D. |
 |
Taligen Therapeutics, Inc. Aurora, Colorado Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. Contact: Ed Hurwitz |
 |
Trevena, Inc. West Conshohocken, Pennsylvania Trevena is a biotechnology company focused on the discovery and development of novel agents targeting G-protein coupled receptors to address a range of diseases. Contact: Farah Champsi |